The coverage of MRD at the meeting, including its impact on future clinical trial design, is discussed. The panel also discusses the promising results of study using nelfinavir and proteasome inhibitor combination therapy for MM. The use of further targeted therapies for MM, as well as their combinations, is also debated. Imaging advances for MM are covered and the future of drug screening on patients’ primary cells is postulated. Lastly, the panel discusses the consensus on the primary principles of MM treatment, which will drive advances in MM research.